Difference between revisions of "Melanoma - historical"
Warner-admin (talk | contribs) m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy") |
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
||
Line 98: | Line 98: | ||
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/abs/10.1200/JCO.1996.14.7.2083 Rusthoven et al. 1996] |
|style="background-color:#1a9851"|Phase III (E) | |style="background-color:#1a9851"|Phase III (E) | ||
|CDB & Tamoxifen | |CDB & Tamoxifen | ||
|style="background-color:#ffffbf"|Seems not superior | |style="background-color:#ffffbf"|Seems not superior | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/abs/10.1200/JCO.1999.17.6.1884 Creagan et al. 1999] |
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
|CDB & Tamoxifen | |CDB & Tamoxifen | ||
Line 120: | Line 120: | ||
===References=== | ===References=== | ||
− | # Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K; National Cancer Institute of Canada Clinical Trials Group. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996 Jul;14(7):2083-90. [ | + | # Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K; National Cancer Institute of Canada Clinical Trials Group. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996 Jul;14(7):2083-90. [https://ascopubs.org/doi/abs/10.1200/JCO.1996.14.7.2083 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8683240 PubMed] |
− | # Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884-90. [ | + | # Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884-90. [https://ascopubs.org/doi/abs/10.1200/JCO.1999.17.6.1884 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561229 PubMed] |
# Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. [http://jco.ascopubs.org/content/20/6/1600.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11896110 PubMed] | # Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. [http://jco.ascopubs.org/content/20/6/1600.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11896110 PubMed] | ||
Line 136: | Line 136: | ||
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/full/10.1200/JCO.2005.03.202 Keilholz et al. 2005 (EORTC 18951)] |
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
|Cisplatin, Dacarbazine, IFN, IL-2 | |Cisplatin, Dacarbazine, IFN, IL-2 | ||
Line 151: | Line 151: | ||
===References=== | ===References=== | ||
− | # '''EORTC 18951:''' Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55. [ | + | # '''EORTC 18951:''' Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55. [https://ascopubs.org/doi/full/10.1200/JCO.2005.03.202 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16170182 PubMed] |
==Cisplatin, Dacarbazine, Tamoxifen {{#subobject:5c5a07|Regimen=1}}== | ==Cisplatin, Dacarbazine, Tamoxifen {{#subobject:5c5a07|Regimen=1}}== | ||
Line 165: | Line 165: | ||
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/full/10.1200/JCO.1999.17.3.968 Rosenberg et al. 1999] |
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
|Cisplatin, Dacarbazine, Tamoxifen, then IFN & IL-2 | |Cisplatin, Dacarbazine, Tamoxifen, then IFN & IL-2 | ||
Line 177: | Line 177: | ||
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
===References=== | ===References=== | ||
− | # Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999 Mar;17(3):968-75. [ | + | # Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999 Mar;17(3):968-75. [https://ascopubs.org/doi/full/10.1200/JCO.1999.17.3.968 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10071291 PubMed] |
==Dacarbazine & Tamoxifen {{#subobject:6d6a07|Regimen=1}}== | ==Dacarbazine & Tamoxifen {{#subobject:6d6a07|Regimen=1}}== |
Revision as of 15:17, 23 June 2019
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main melanoma page for current regimens.
20 regimens on this page
34 variants on this page
|
Metastatic or unresectable disease
BCG & Dacarbazine
back to top |
BCG & DTIC: Bacillus Calmette-Guérin & Dimethyl Triazeno Imidazole Carboxamide (Dacarbazine)
Regimen
Study | Evidence |
---|---|
Gutterman et al. 1974 | Non-randomized |
Immunotherapy
Chemotherapy
References
- Gutterman JU, Mavligit G, Gottlieb JA, Burgess MA, McBride CE, Einhorn L, Freireich EJ, Hersh EM. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and Bacillus Calmette--Guérin. N Engl J Med. 1974 Sep 19;291(12):592-7. link to original article PubMed
BHD
back to top |
BHD: BCNU (Carmustine), Hydroxyurea, Dacarbazine
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Costanzi et al. 1984 (SWOG S7727) | Phase III (C) | 1. BHD & Levamisole 2. DTIC & Dactinomycin |
Seems not superior |
Chemotherapy
References
- SWOG S7727: Costanzi JJ, Fletcher WS, Balcerzak SP, Taylor S, Eyre HJ, O'Bryan RM, Al-Sarraf M, Frank J. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Cancer. 1984 Feb 15;53(4):833-6. link to original article PubMed
BVD
back to top |
BVD: BCNU (Carmustine), Vincristine, Dacarbazine
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Jelić et al. 2002 | Phase III (C) | 1. High-dose BVD 2. Bleomycin, Cisplatin, Vindesine 3. Carmustine & Procarbazine |
Seems not superior |
Chemotherapy
References
- Jelić S, Babovic N, Kovcin V, Milicevic N, Milanovic N, Popov I, Radosavljevic D. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. Melanoma Res. 2002 Feb;12(1):91-8. link to original article PubMed
CDB
back to top |
CDB: Cisplatin, Dacarbazine, BCNU (Carmustine)
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Rusthoven et al. 1996 | Phase III (E) | CDB & Tamoxifen | Seems not superior |
Creagan et al. 1999 | Phase III (C) | CDB & Tamoxifen | Seems not superior |
Ridolfi et al. 2002 | Phase III (C) | Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine | Seems not superior |
Chemotherapy
References
- Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K; National Cancer Institute of Canada Clinical Trials Group. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996 Jul;14(7):2083-90. link to original article PubMed
- Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884-90. link to original article PubMed
- Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. link to original article contains verified protocol PubMed
Cisplatin, Dacarbazine, Interferon alfa-2b
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Keilholz et al. 2005 (EORTC 18951) | Phase III (C) | Cisplatin, Dacarbazine, IFN, IL-2 | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
28-day cycle for up to 4 cycles
References
- EORTC 18951: Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55. link to original article PubMed
Cisplatin, Dacarbazine, Tamoxifen
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Rosenberg et al. 1999 | Phase III (C) | Cisplatin, Dacarbazine, Tamoxifen, then IFN & IL-2 | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
References
- Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999 Mar;17(3):968-75. link to original article PubMed
Dacarbazine & Tamoxifen
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Cocconi et al. 1992 | Phase III (E) | Dacarbazine | Seems to have superior OS |
Chemotherapy
References
- Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992 Aug 20;327(8):516-23. link to original article PubMed